Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

INTRODUCTION: Subcutaneous versions of different oncology therapies have been available for patients for a few years, yet patient-relevant and hospital benefits have not been assessed in real life. METHODS: In order to analyze the impact of subcutaneous administrations for rituximab or trastuzumab i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponzetti, Clemente, Canciani, Monica, Farina, Massimo, Era, Sara, Walzer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883807/
https://www.ncbi.nlm.nih.gov/pubmed/27284260
http://dx.doi.org/10.2147/CEOR.S97319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883807/
https://www.ncbi.nlm.nih.gov/pubmed/27284260
http://dx.doi.org/10.2147/CEOR.S97319

Ejemplares similares